Kent T. Symons

DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras

Xiaoyu Zhang, Lena Luukkonen, Christie L. Eissler et al. · Journal of the American Chemical Society · 2021 · 183 citations · Full text

Proteomic Technology, Androgen Receptor, Protein Function +14

Three-Dimensional Fibroblast Culture Implant for the Treatment of Diabetic Foot Ulcers: Metabolic Activity and Therapeutic Range

Jonathan Mansbridge, Kang Liu, Ruth Patch et al. · Tissue Engineering · 1998 · 140 citations

Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase

Kristen A. Baltgalvis, Kelsey N. Lamb, Kent T. Symons et al. · Nature · 2024 · 88 citations

Molecular Recognition, Biochemistry, Natural Sciences +6

Discovery of Inducible Nitric Oxide Synthase (iNOS) Inhibitor Development Candidate KD7332, Part 1: Identification of a Novel, Potent, and Selective Series of Quinolinone iNOS Dimerization Inhibitors that are Orally Active in Rodent Pain Models

Céline Bonnefous, Joseph E. Payne, Jeffrey Roppe et al. · Journal of Medicinal Chemistry · 2009 · 69 citations · Full text

Pain Medicine, Nitric Oxide, Molecular Pain +17

Discovery of Dual Inducible/Neuronal Nitric Oxide Synthase (iNOS/nNOS) Inhibitor Development Candidate 4-((2-Cyclobutyl-1<i>H</i>-imidazo[4,5-<i>b</i>]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1<i>H</i>)-one (KD7332) Part 2: Identification of a Novel, Potent, and Selective Series of Benzimidazole-Quinolinone iNOS/nNOS Dimerization Inhibitors That Are Orally Active in Pain Models

Joseph E. Payne, Céline Bonnefous, Kent T. Symons et al. · Journal of Medicinal Chemistry · 2010 · 57 citations · Full text